Premium
CD95‐mediated apoptosis: no variation in cellular sensitivity during cell cycle progression
Author(s) -
Hueber Arno,
Durka Silke,
Weller Michael
Publication year - 1998
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(98)00855-2
Subject(s) - cell cycle , apoptosis , hela , fas receptor , cell cycle checkpoint , cell , biology , cancer research , microbiology and biotechnology , fas ligand , jurkat cells , programmed cell death , immunology , t cell , biochemistry , immune system
Sensitivity of CD95‐mediated apoptosis has been reported to vary during cell cycle progression (FEBS Lett. (1997) 412, 91–93). Here, we report that three human glioma cell lines with different p53 status (i) undergo growth arrest and synchronous cell cycle re‐entry after prolonged serum deprivation, (ii) do not exhibit cell cycle‐related changes in CD95 expression at the cell surface, and (iii) do not exhibit cell cycle‐related changes in susceptibility to DC95 ligand‐induced apoptosis. In contrast, cell cycle‐specific activity was demonstrated for various cancer chemotherapy drugs. Further, CD95 expression and susceptibility to CD95 ligand‐induced apoptosis does not vary during cell cycle progression of Jurkat T cells, HeLa cervical carcinoma and HepG2 hepatocellular carcinoma cells. These results do not support a role for the cell cycle phase as an important predictor of vulnerability to CD95‐mediated apoptosis.